Business Wire

SmartStream Furthers Its Alliance With Acadia by Automating Collateral Substitutions Movements

10.5.2023 11:00:00 EEST | Business Wire | Press release

Share

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the continuation of its partnership with Acadia, the provider of margin automation services – enabling increased efficiencies for the processing and calculation of substitutions movements for TLM Collateral Management customers, and their associated counterparties.

SmartStream’s TLM Collateral Management solution will work alongside Acadia’s Substitutions Workflow, available via its Margin Manager product. The module will integrate with the workflow to automate the two-way communication and substitution coordination between counterparties. This allows users to manage substitution details throughout the workflow lifecycle in a standardised messaging format. This is invaluable for clients who are optimising their collateral and who are often faced with a trade-off between optimising their collateral in-order-to reduce funding costs, and manual operational work to manage substitutions. The new module will provide exceptions-based processing and will promote STP for collateral substitutions.

Will Thomey, Co-Head Business Development, Acadia, states: “It is a great pleasure to continue our relationship with SmartStream. Over the past two years we have made progress by transforming the way our clients manage their collateral. Helping customers optimise their collateral and better manage substitutions allows them to gain transparency and control over their risk exposure and costs. This is another example of serving our clients by continuing to invest in the collateral or margin workflow, whilst also meeting their business efficiency goals”.

Jason Ang, Program Manager, TLM Collateral Management, SmartStream, states: “We value our excellent relationship with Acadia, together we have benefitted our clients in the collateral management area. Given the current emphasis for optimisation in the market, we see that there will be an increase in substitutions requests. These requests traditionally have been a time-consuming process, but we have worked with Acadia to provide an automated solution to help our clients save time, reduce manual work, and automate the process. TLM Collateral Management coupled with Acadia’s Margin Manager provides integration with a powerful collateral management solution, and a user-friendly dashboard allowing for quick exception management, with a complete audit trail with final statements. We strive to continually improve service for our clients, and this is a great addition to our existing solution”.

Ang continues: “In addition, this collaboration with Acadia and several Tier 1 financial institutions further validates the need for our industry partners to shorten the settlement cycle, to help with industry efforts such as T+1 and CSDR initiatives – this is becoming of increased importance as deadlines come closer”.

Ends

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Shamira Alidina, Media Relations Director, Dina Communications
Tel: +44 (0) 7801 590718
Email: shamira@dinacomms.com

Nathan Gee, Marketing Director, SmartStream Technologies
Tel: +44 (0) 20 7898 0630
Email: nathan.gee@smartstream-stp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye